Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 1.00 |
| ▸ | ACE | P12821 | 3/20 | 1.00 |
| ▸ | MME | P08473 | 3/20 | 1.00 |
| ▸ | NPPA | P01160 | 1/20 | 1.00 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.39 |
| ▸ | CHRND | Q07001 | 5/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | CHRNG | P07510 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sampatrilat SCHEMBL4567110 | 1.00 | ECE1 (1.00) | ECE1ACEMMENPPAITGB3 | |
| Sampatrilat SCHEMBL7301333 | 1.00 | ECE1 (1.00) | ECE1ACEMMENPPAITGB3 | |
| SCHEMBL7294367 | 0.95 | ACE (0.91) | ECE1ACEMMENPPAITGB3 | |
| SCHEMBL7302871 | 0.90 | MME (0.82) | ECE1ACEMMENPPAITGB3 | |
| SCHEMBL7302883 | 0.90 | MME (0.82) | ECE1ACEMMENPPAITGB3 | |
| SCHEMBL9755064 | 0.90 | MME (0.81) | ECE1ACEMMENPPAITGB1 | |
| SCHEMBL6441043 | 0.90 | ACE (0.81) | ECE1ACEMMENPPAITGB3 | |
| SCHEMBL9755065 | 0.90 | MME (0.81) | ECE1ACEMMENPPAITGB1 | |
| SCHEMBL7294361 | 0.89 | MME (0.80) | ECE1ACEMMENPPAITGB3 | |
| SCHEMBL10471733 | 0.88 | ECE1 (0.77) | ECE1ACEMMENPPAITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3724 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022265697-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | Tiger Development, LLC (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220370360-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | ACCESS TO ADVANCED HEALTH INSTITUTE | 2022-11-24 | — | — | US | claimed |
| US-20210401751-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | Tiger Development Inc. (US) | 2021-12-30 | — | — | US | claimed |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-09 | — | — | US | claimed |
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | claimed |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-14 | — | — | US | claimed |
| US-10149909-B2 | Fortifier | TORAY INDUSTRIES, INC. (JP) | 2018-12-11 | — | — | US | claimed |
| WO-2018211479-A1 | STABILIZED COMPOSITIONS OF ANGIOTENSIN II INHIBITORS AND NEUTRAL ENDOPEPTIDASE INHIBITORS AND PROCESS FOR PREPARATION THEREOF | LUPIN LIMITED (IN) | 2018-11-22 | — | — | WO | claimed |
| US-10131671-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-11-20 | — | — | US | claimed |
| EP-2661431-B1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2018-07-11 | — | — | EP | claimed |
| US-20030065040-A1 | Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle | SUPERNUS PHARMACEUTICALS, INC | 2003-04-03 | — | — | US | claimed |
| US-20030050301-A1 | Combination of aldose reductase inhibitors and angiotensin-II antagonists for the treatment of diabetic nephropathy | MYLARI BANAVARA L (US) | 2003-03-13 | — | — | US | claimed |
| WO-2002087621-A1 | PHARMACEUTICAL COMPOSITION INCLUDING ACE/NEP INHIBITORS AND BIOAVAILABILITY ENHANCERS | SHIRE LABORATORIES INC. (US) | 2002-11-07 | — | — | WO | claimed |
| WO-2002060437-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING SAMPATRILAT DISPERSED IN A LIPOIDIC VEHICLE | SHIRE LABORATORIES, INC. (US) | 2002-08-08 | — | — | WO | claimed |
| WO-2002058793-A1 | ESSENTIAL N-3 FATTY ACIDS IN CARDIAC INSUFFICIENCY AND HEART FAILURE THERAPY | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-01 | — | — | WO | claimed |
| US-20020068740-A1 | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications | MYLARI BANAVARA L (US) | 2002-06-06 | — | — | US | claimed |
| EP-1059918-A1 | NOVEL DOSAGE FORM | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited (GB) | 2000-12-20 | — | — | EP | claimed |
| WO-1999037290-A1 | NOVEL DOSAGE FORM | WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINICAL RESEARCH CENTRE LIMITED (GB) | 1999-07-29 | — | — | WO | claimed |
| EP-0358398-B1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1993-03-10 | — | — | EP | claimed |
| EP-0358398-A1 | Cycloalkyl-substituted glutaramide antihypertensive agents | Pfizer Limited (GB) | 1990-03-14 | — | — | EP | claimed |